Ozempic and Wegovy are no longer in shortage, FDA says
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.
U.S. FDA Declares Shortage of Novo Nordisk's Wegovy, Ozempic Over — Update
The U.S. Food and Drug Administration declared that the shortage of Novo Nordisk's weight-loss medications Wegovy and Ozempic has been resolved, according to its website. The FDA announcement confirms ...
BioPharma Dive3h
Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair
The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...
A Lawsuit Has Been Filed Against Novo Nordisk A/S For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of ...
Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
FDA Declares Shortage of Novo Nordisk’s Wegovy, Ozempic Over
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...
U.S. Drug Regulator Declares Wegovy, Ozempic Shortage Over, Novo Nordisk Says
The U.S. drug regulator declared that the shortage of weight-loss medications Wegovy and Ozempic has been resolved, Danish pharma giant Novo Nordisk said.
FDA declares Wegovy and Ozempic shortage over, Novo Nordisk confirms
Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration has determined the shortage of Wegovy and Ozempic is resolved. “The ...
FiercePharma5h
Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
FiercePharma7h
Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
The next phase of the weight-loss revolution holds promise — and peril
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Zealand Pharma steadfastly upholds amylin-based obesity drug strategy
Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...